Navigation Links
Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,,,Transactivators

s elaborate networks of signaling molecules (e.g., receptors, protein kinases, and phosphatases) organized in linear or parallel pathways.1,2 These signaling pathways receive diverse upstream signals that cause distinct downstream changes. Among the better-characterized signal transduction pathways are the cAMP-dependent protein kinase (PKA) pathway and the mitogen-activated protein kinase (MAPK) pathways. When activated by upstream signals, PKA or MAPK translocates into the nucleus and activates transcription factors, such as CREB and Elk1.3 Thus, the activation level of the transcription factors reflects the status of the respective kinases and upstream signaling molecules along the pathway.

To facilitate studies on the in vivo functions of gene products or extracellular stimuli, Stratagene developed the PathDetect trans-reporting systems using GAL4 fusion transactivators as pathway-specific sensors.4,5,6,7 In these systems, a fusion trans-activator plasmid that consists of the DNA binding domain of the yeast GAL4 (residues 1 to 147) protein8 and the activation domain of CREB, Elk1, or c-Jun is used to probe the activity of PKA, MAPK, and JNK, respectively.4-7,9,10 These fusion trans-activators bind to the promoter in the pFR-Luc reporter plasmid, which contains five direct repeats of the GAL4-binding element and controls luciferase expression.4 Either direct or indirect phosphorylation of the activation domain of a fusion trans-activator protein by an uncharacterized gene product activates transcription of the luciferase gene. Thus, expression levels of luciferase reflect the activation status of the respective kinases that define the signal transduction pathways.

To offer expanded capability for studying signal transduction and improved performance for adaptation to high-throughput applications, Stratagene has developed stable HeLa re
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
2. Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39)
3. Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38)
4. Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar
5. Versatile Reporter Vectors for Monitoring Viral Transduction
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. Genetic Reporter Systems
8. Genetic Reporter Systems
9. Detection of Reporter Gene Activity in Cell Cultures and Murine Epidermis After Helios Gene Gun-Mediated Particle Bombardment
10. A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20)
11. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
Post Your Comments:
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ... "Global PDT Machine Industry Report 2014" report ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global PDT ... in-depth study on the current state of the ... overview of the industry including definitions, classifications, applications ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
(Date:6/1/2015)... , June 1, 2015 Esperance Pharmaceuticals ... trial of lead candidate EP-100 in ovarian cancer patients ... designed to seek and destroy cancer cells that overexpress ... receptors are over-expressed in a wide range of cancers. ... Phase II trial of EP-100 were presented at ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global PDT Machine Industry Report 2014 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... July 7 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the "Company") (Nasdaq: CHBT ... , today provides,further updates on the Company,s bulk additive operation. , ... China-Biotics gained ... and the total number of bulk customers increased to 39 by the ...
... , ... that from a single platform, scientists can efficiently profile lead compounds in their own ... ... -- Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete ...
... CLEVELAND , July 7 DATATRAK International, Inc. ... eClinical solutions for the clinical trials industry, today announced that ... approximately $0.53 per share with certain members of ... sold pursuant to the private placement are restricted securities and ...
Cached Biology Technology:China-Biotics Provides Further Updates on Qingpu New Facility 2China-Biotics Provides Further Updates on Qingpu New Facility 3Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... the word "doctor" to mean "all-knowing," unfortunately, this will ... of medical professionals sometimes leads to devastating misdiagnoses that ... their patients. , But there is hope for better, ... technologies, and one Florida State University researcher is putting ...
... data for E7389 in the treatment of advanced, refractory ... E7389 is a synthetic analog of halichondrin B ... studies to have highly potent anti-cancer activity in vitro ... a type of marine sponge. , This study was ...
... shown that the immune-stimulating hormone known as interleukin-12 ... immune-system protein, as an experimental therapy for some ... to stimulate the immune system to attack certain ... sometimes used to treat melanoma, advanced kidney cancer ...
Cached Biology News:Making medicine 'smarter' 2Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer 2Study shows combination of immune substances to be safe 2
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: D-hexose ... 2.7.1.1/1.1.1.49. One unit of HK ... D-glucose in 1 min at ... unit of G6P-DH will oxidize ...
Request Info...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
Biology Products: